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Abstract
Background: Phthalates and BPA are endocrine disrupting chemicals (EDCs) widely used in consumer products.
Evidence suggests that phthalate and BPA exposure alters steroid hormone levels in adults, while in utero exposure
has been associated with altered fetal reproductive development in boys. However, the impact of exposure during
distinct critical windows of in utero development on hormone concentrations and sexual maturation during the
pubertal transition has not been examined. The objective of this study was to assess trimester-specific in utero
phthalate and BPA exposure in relation to measures of reproductive development among peripubertal boys in a
Mexico City birth cohort.
Methods: We measured maternal urinary phthalate metabolites and BPA during the first, second, and third
trimesters of pregnancy. We measured serum levels of testosterone, estradiol, dehydroepiandrosterone sulfate
(DHEA-S), inhibin B, and sex hormone-binding globulin (SHBG), and assessed sexual maturation (Tanner staging and
testicular volume) among male children at age 8–14 years (n = 109). Linear and logistic regression were used to
investigate trimester-specific in utero exposure as predictors of peripubertal hormone levels and sexual maturation,
respectively. In sensitivity analyses we evaluated estimated exposure at 7 weeks gestation and rates of change in
exposure across pregnancy in relation to outcomes.
Results: Exposure to phthalates during the third trimester was associated with reduced odds of having a Tanner
stage >1 for pubic hair development (e.g. MBzP OR = 0.18 per interquartile range (IQR) increase; 95% CI:0.03–0.97)
and higher peripubertal SHBG levels (e.g. MBzP 15.2%/IQR; 95% CI:3.2–28%), while first and second trimester
phthalates were not. In contrast, exposure to DEHP during the first trimester was associated with higher estradiol
(11%/IQR; 95% CI:1.5–22%), while second or third trimester DEHP exposure was not. Sensitivity analyses yielded
similar findings.
Conclusions: Associations between in utero phthalate and BPA exposure and peripubertal measures of male
reproductive development are dependent on the timing of that exposure during gestation. These findings suggest
that future epidemiological studies relating in utero EDC exposure to pubertal outcomes should consider windows
of susceptibility.
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Background
Phthalates and bisphenol A (BPA) are endocrine disrupt-
ing chemicals (EDCs) [1] that are widely used in a range
of consumer products, resulting in ubiquitous human
exposure [2–4]. Evidence suggests that exposure to
phthalates and BPA alters reproductive hormone levels
in adults [5–9], while exposure during in utero devel-
opment has been associated with changes in reproduct-
ive hormone levels in newborns [10, 11]. In addition,
several studies have reported associations between in
utero phthalate exposure and shortened anogenital dis-
tance (AGD) [12–14], a marker of decreased androgen
exposure during in utero reproductive development
and a potential indicator of reduced male fertility in
adulthood [15, 16]. However, the impact of in utero
phthalate and BPA exposure on peripubertal reproduct-
ive hormone concentrations and sexual maturation is
unclear.
In earlier work, we reported that phthalate exposure
during the third trimester of in utero development was
associated with lower odds of adrenarche, while peripu-
bertal exposure was not [17]. Given that androgen ac-
tion during relatively short, specific fetal periods is
necessary for male reproductive development [18, 19],
the objective of the present analysis was to utilize newly
available data to assess early in utero windows of sus-
ceptibility to phthalate and BPA exposure among boys
in this study population. To our knowledge, this is the
first study to evaluate maternal urinary phthalate me-
tabolite and BPA concentrations during their first, sec-
ond, and third trimesters of pregnancy, as well as the
level and rate of change of exposure across pregnancy,
in relation to peripubertal reproductive hormone levels




Participants are part of the Early Life Exposure in
Mexico to Environmental Toxicants (ELEMENT) pro-
ject, a longitudinal cohort study of pregnant women in
Mexico City and their offspring. Our analysis includes
women who were recruited from maternity hospitals
during their first trimester between 1997 and 2004 and
their offspring as previously described [20]. Mothers
provided a urine sample and completed interview-based
questionnaires at up to three different prenatal visits
(mean gestational age at visit 1: 13.5 weeks [range 5–24],
visit 2: 25.1 weeks [range 17–37], and visit 3: 34.4 weeks
[range 26–43]). Gestational age was based on the self-
reported date of each mother’s last menstrual period. In
2010, a subset of their children, who were then 8 to
14 years of age, were re-contacted to participate in
follow-up studies (n = 250). Participants were selected
from the overall ELEMENT study based on the availability
of archived prenatal urine samples for biomarker measure-
ment. Children provided serum samples, anthropometry,
and demographic information via an interview-based
questionnaire. Age-specific body mass index (BMI) z-
scores were calculated based on the World Health
Organization growth standards for age and sex [21]. In
the current analyses, we included male children for
whom we had maternal urinary phthalate metabolite
and BPA measurements from at least one prenatal
study visit (n = 109). Research protocols were approved
by the ethics and research committees of the Mexico
National Institute of Public Health and the University
of Michigan, and all participants provided informed
consent prior to enrollment.
Urinary phthalate metabolites and BPA
Each mother provided a second morning void urine
sample during at least one of the three prenatal study
visits (visit 1 n = 92, visit 2 n = 91, visit 3 n = 108;
n = 85 provided a sample at all three time points). Sam-
ples were frozen and stored at −80 °C at the University
of Michigan until analysis at NSF International (Ann
Arbor, MI). BPA and nine phthalate metabolites, includ-
ing monoethyl phthalate (MEP), mono-n-butyl phthalate
(MnBP), monoisobutyl phthalate (MiBP), monobenzyl
phthalate (MBzP), mono-3-carboxypropyl phthalate
(MCPP), mono-2-ethylhexyl phthalate (MEHP),
mono-2-ethyl-5-hydroxyhexyl phthalate (MEHHP),
mono-2-ethyl-5-oxohexyl phthalate (MEOHP), and
mono-2-ethyl-5-carboxypentyl phthalate (MECPP) were
measured using isotope dilution–liquid chromatography–
tandem mass spectrometry (ID–LC–MS/MS) as previ-
ously described [20]. We calculated a di-2-ethylhexyl
phthalate (DEHP) metabolite summary measure (ΣDEHP)
for each sample by dividing individual MEHP, MEHHP,
MEOHP, and MECPP concentrations by their molar mass
and summing them. We calculated a summary dibutyl
phthalate (DBP) metabolite measure (ΣDBP) as the molar
sum of MnBP and MiBP. Specific gravity (SG) was
measured using a handheld digital refractometer (Atago
Co., Ltd., Tokyo, Japan) at the time of sample analysis.
For select analyses only, phthalate metabolite and BPA
values were corrected for urinary SG using the following
equation: Pc = P[(SGp – 1)/(SGi – 1)] where Pc is the SG-
corrected phthalate metabolite or BPA concentration (ng/
mL), P is the measured phthalate metabolite or BPA con-
centration, SGp is the median urinary specific gravity, and
SGi is the individual’s urinary specific gravity. Spearman
correlations between trimester specific measures of
SG, phthalate metabolites, and BPA are presented in
(Additional file 1: Table S1). Values below the limit of
detection (LOD) were replaced with the LOD/√2.
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Hormones
Children provided fasting blood samples during the
follow-up visit at age 8–14 years. Serum aliquots were
separated and frozen at −80 °C, and then sent to the
Clinical Ligand Assay Service Satellite (CLASS) Labora-
tory at the University of Michigan (Ann Arbor, MI) for
hormone analysis. We measured estradiol, testosterone,
inhibin B, and sex hormone-binding globulin (SHBG) as
biomarkers of puberty, and dehydroepiandrosterone sul-
fate (DHEA-S) as a biomarker of adrenarche. Estradiol,
total testosterone, SHBG, and DHEA-S were measured
using an automated chemiluminescent immunoassay
(Bayer Diagnostics ACS:180). Active inhibin B was assayed
using Gen II ELISA (Beckman Coulter, Webster, TX).
Values below the limit of detection (LOD) were replaced
with the LOD/√2.
Sexual maturation
A trained pediatrician evaluated male offspring for Tan-
ner staging and testicular volume using standardized
protocols. We used genital stage (GD) as an indicator of
puberty and pubic hair stage (PH) as an indicator of
adrenarche, with stage 1 corresponding to no develop-
ment and stage 5 corresponding to full development
[22]. For analyses, Tanner stages were converted to di-
chotomous variables with pubertal onset defined by hav-
ing a GD stage >1 and adrenarche defined by having a
PH stage >1. Right and left testicular volume (TV) were
measured with an orchidometer, and the larger of the
two measurements was used in analyses. As a testicular
volume of 1–3 mL is considered prepubertal, a cutoff of
3 mL was used to denote no puberty (≤3 mL) vs. puberty
(>3 mL) [23].
Statistical methods
Serum hormone and urinary phthalate metabolite and
BPA concentrations were log-normally distributed, and
ln-transformed prior to analysis. We used mixed models
to calculate intraclass correlation coefficients (ICCs) and
95% confidence intervals to examine the variability of
phthalate and BPA measurements across pregnancy
within individuals with more than one exposure meas-
urement [24]. Linear regression was used to separately
assess associations between visit-specific phthalate me-
tabolite and BPA concentrations and peripubertal serum
hormone concentrations, adjusting a priori for child age
and BMI Z-score, and for SG as a measure of urinary di-
lution. To assess overall exposure during pregnancy, we
calculated geometric mean (GM) phthalate metabolite
and BPA concentrations for each individual using all
available measurements from prenatal visits 1, 2, and 3.
If only one measurement from one prenatal visit was
available, that value was used as the GM. Individual GM
values were then entered into regression models to assess
relationships between overall in utero exposure and peri-
pubertal hormone levels. Results are presented as the per-
cent change in hormone (95% confidence interval) per
interquartile range (IQR) increase in phthalate metabolite
or BPA. All results are calculated based on the IQR of GM
concentrations across pregnancy in order to more easily
compare visit-specific effect estimates.
We used logistic regression to separately examine
associations between visit-specific urinary phthalate
metabolite or BPA concentrations and the odds of puber-
tal onset or adrenarche using dichotomous measures of
sexual maturation (GD, PH, TV). In full models, child age
and BMI z-score were included as covariates a priori. As
few participants were categorized as having a PH Tanner
stage >1 (Additional file 1: Table S2), the number of co-
variates we could reliably enter into models was limited
[25, 26]. Thus, to minimize the number of covariates in
logistic models, we included SG-corrected phthalate
metabolite and BPA concentrations rather than enter-
ing SG as a separate covariate. Individual GM phthalate
metabolite and BPA values were also entered into logis-
tic regression models to assess relationships of overall
in utero exposure with odds of pubertal onset and adre-
narche. Results are presented as odds ratios (OR, 95%
confidence interval), which express the change in odds
per IQR increase in exposure, with the IQR based on
GM concentrations across pregnancy.
We carried out complementary, sensitivity analyses for
each exposure that utilized data from all participants
and all visits in a single model to examine whether the
level (intercept) or rate of change (slope) of the exposure
during pregnancy was associated with hormone concen-
trations or sexual maturation. To carry out this analysis,
we first used mixed effects models with gestational age
as a predictor of ln-transformed, SG-corrected phthalate
or BPA concentrations to estimate, for each woman and
each compound, a random intercept and slope that de-
scribed the compound’s trajectory during the course of
pregnancy. Prior to entering gestational age into the
model, it was centered at 7 weeks, such that an individual’s
intercept represents urinary phthalate metabolite or BPA
concentrations at 7 weeks, the mid-point of the first tri-
mester of pregnancy. An individual’s slope indicates the
rate of change in urinary phthalate metabolite or BPA
across pregnancy. For each exposure, we then entered the
estimated slope and intercept variables into regression
models as predictors of either hormone concentrations or
measures of sexual maturation. However, if the slope and
intercept for a specific phthalate metabolite or BPA were
highly correlated (Pearson r > 0.8), or if effect estimates
were imprecise (e.g. infinitely wide 95% confidence inter-
vals), only the intercept was used. Findings were consid-
ered statistically significant at p < 0.05, and all analyses
were performed using SAS version 9.3 (Cary, NC).
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Results
The percent of samples with phthalate metabolite or
BPA concentrations below the limit of detection, as well
as the geometric means and standard deviations of
sample concentrations from prenatal visits 1, 2, and 3
are shown in Table 1. Urinary BPA concentrations sig-
nificantly decreased, while MBzP, MEOHP, and MiBP
concentrations significantly increased across pregnancy.
ICCs for phthalate metabolite and BPA concentrations
among all mothers ranged from 0.21 for MBzP to 0.41
for MEP, suggesting substantial within individual vari-
ability. Differences in levels across pregnancy and the
percent of samples below the LOD were similar when
we limited our analysis to only mothers who had male
children, although ICCs ranged from 0.14 for ΣDEHP
to 0.47 for MEP. The distribution of serum hormone
levels and measures of sexual maturation among this
population have been previously reported elsewhere [17].
Maternal phthalate metabolite and BPA concentrations
at prenatal visit 1 were not associated with peripubertal
hormone levels in male offspring at 8–14 years of age,
with the exception of ΣDEHP, for which an IQR increase
was associated with 11% (95% CI: 1.5, 21.9) higher
serum estradiol after adjustment for child age, BMI z-
score, and urinary SG (Table 2). At prenatal visit 2, an
IQR increase in MEP was associated with 15% (95%
CI: −25.1, −3.6) lower estradiol concentrations, while
an IQR increase in MBzP was associated with 16%
(95% CI: −26.8, −3.4) lower DHEA-S. Maternal BPA
concentrations at prenatal visit 2 were also associated
Table 1 Distribution of urinary phthalate metabolites and BPA across pregnancy (μg/L)
Visit 1 (n = 199) Visit 2 (n = 200) Visit 3 (n = 225) Prenatal GM (n = 229) Variability
All % < LODa GM (GSD) Max GM (GSD) Max GM (GSD) Max GM (GSD) Max ICC (95% CI)
BPAb 23.6 1.0 (2.5) 9.3 1.0 (2.4) 13.2 0.7 (2.30 18.7 0.89 (2.0 6.9 0.32 (0.24, 0.41)
MEHP 8.0 4.9 (2.8) 125 4.7 (2.9) 152 5.0 (2.8) 215 5.0 (2.2) 215 0.25 (0.17, 0.35)
MEHHP 0 16.6 (3.1) 158 17.4 (3.2) 1290 19.6 (2.9) 383 18.6 (2.3) 383 0.23 (0.15, 0.33)
MEOHPb 0 8.9 (3.1) 85.0 10.4 (3.2) 730 11.8 (2.9) 244 10.8 (2.3) 244 0.23 (0.15, 0.33)
MECPP 0.2 30.0 (2.7) 252 31.9 (2.7) 2650 31.9 (2.7) 414 32.3 (2.1) 414 0.26 (0.18, 0.36)
MBzPb 3.2 2.6 (4.0) 69.6 2.4 (3.6) 38.5 4.2 (2.6) 109 3.2 (2.4) 34.5 0.21 (0.14, 0.31)
MBP 0.3 59.0 (4.1) 1340 49.0 (3.8) 1390 54.5 (3.4) 1190 56.0 (2.6) 468 0.28 (0.20, 0.38)
MiBPb 22.0 0.92 (4.7) 118 0.7 (4.6) 26.5 1.9 (2.9) 40.1 1.2 (2.9) 32.4 0.31 (0.23, 0.40)
MCPP 8.0 1.1 (2.9) 17.8 1.1 (2.8) 15.0 1.1 (2.7) 12.1 1.1 (2.2) 6.6 0.31 (0.23, 0.40)
MEP 0.3 138 (4.2) 4480 119 (3.9) 4980 112 (4.2) 9810 126 (3.1) 2285 0.41 (0.33, 0.50)
ΣDEHPc 0.21 (2.7) 1.7 0.22 (2.9) 16.0 0.24 (2.7) 4.3 0.23 (2.1) 4.3 0.24 (0.16, 0.34)
ΣDBPd 0.27 (4.1) 6.1 0.23 (3.7) 6.3 0.26 (3.3) 5.4 0.26 (2.6) 2.2 0.28 (0.20, 0.38)
Visit 1 (n = 92) Visit 2 (n = 91) Visit 3 (n = 108) Prenatal GM (n = 109) Variability
Males % < LOD GM (GSD) Max GM (GSD) Max GM (GSD) Max GM (GSD) Max ICC (95% CI)
BPAb 26.8 0.93 (2.5) 7.9 0.87 (2.3) 9.2 0.64 (2.3) 9.0 0.81 (1.9) 4.5 0.28 (0.17, 0.42)
MEHP 7.9 4.8 (2.6) 53.0 4.4 (2.8) 50.3 5.0 (2.9) 215 5.0 (2.2) 215 0.28 (0.17, 0.43)
MEHHP 0 15.6 (3.4) 150 15.7 (3.0) 85.0 19.9 (2.9) 383 18.0 (2.3) 383 0.15 (0.06, 0.33)
MEOHPb 0 8.3 (3.3) 80.2 9.4 (3.0) 53.5 12.0 (2.8) 244 10.4 (2.3) 244 0.15 (0.06, 0.33)
MECPP 0.3 28.5 (2.9) 227 29.4 (2.5) 134 32.7 (2.5) 414 31.5 (2.1) 414 0.15 (0.05, 0.33)
MBzPb 3.4 2.4 (4.3) 51.3 2.5 (3.8) 34.5 4.3 (2.5) 32.5 3.3 (2.5) 34.5 0.15 (0.06, 0.33)
MBP 0.7 54.1 (4.2) 870 42.3 (3.7) 655 53.9 (3.1) 1000 53.0 (2.6) 468 0.24 (0.14, 0.40)
MiBPb 25.1 0.76 (4.7) 118 0.62 (4.5) 25.8 1.7 (2.8) 40.1 1.1 (2.9) 32.4 0.32 (0.21, 0.46)
MCPP 7.2 1.1 (2.7) 9.8 1.1 (2.7) 8.2 1.1 (2.6) 12.1 1.1 (2.1) 6.0 0.27 (0.16, 0.41)
MEP 0.3 128 (4.2) 3260 117 (3.6) 2160 110 (3.7) 7950 124 (3.0) 2285 0.47 (0.36, 0.60)
ΣDEHPc 0.20 (2.9) 1.6 0.20 (2.7) 0.93 0.24 (2.6) 4.3 0.22 (2.1) 4.3 0.14 (0.05, 0.32)
ΣDBPd 0.25 (4.1) 4.5 0.20 (3.7) 3.0 0.25 (3.1) 4.5 0.25 (2.6) 2.1 0.25 (0.15, 0.40)
LOD limit of detection, GM geometric mean of samples collected during pregnancy, GSD geometric standard deviation, ICC intraclass correlation coefficient,
CI confidence interval
aLODs: BPA = 0.4, MEHP, MEP = 1.0, MEHHP, MEOHP = 0.1, MECPP, MBzP, MiBP, MCPP = 0.2, MBP = 0.5; bConcentrations were significantly different across
prenatal visits (p < 0.05); cΣDEHP = molecular sum of MEHP, MEHHP, MEOHP, and MECPP (μmol/L); dΣDBP = molar sum of MnBP and MiBP (μmol/L)
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with higher inhibin B levels, and MBzP, MCPP, and
ΣDBP at prenatal visit 3 were all associated with higher
SHBG levels. Geometric mean levels of phthalate metabol-
ite and BPA concentrations across pregnancy were not sig-
nificantly associated with peripubertal serum hormone
concentrations (Table 2).
Although logistic regression models including SG as a
separate covariate (Additional file 1: Table S3) yielded
results similar to models including SG-corrected phthal-
ate metabolite and BPA values, the latter generally pro-
vided narrower confidence intervals. Therefore, we have
presented ORs from models with SG-corrected exposure
Table 2 Percent difference in peripubertal hormone levels associated with an IQR increase in phthalate metabolite or BPA
concentration during trimester-specific in utero developmenta
Visit 1 (n = 91) Visit 2 (n = 90) Visit 3 (n = 107) Prenatal GM (n = 108)
%Δ/IQR (95% CI) %Δ/IQR (95% CI) %Δ/IQR (95% CI) %Δ/IQR (95% CI)
Estradiol
BPA −1.1 (−10.8, 9.7) −4.5 (−14.2, 6.2) 0.1 (−9.1, 10.2) −2.4 (−13.7, 10.4)
MBzP 5.0 (−3.5, 14.3) 0.7 (−9.2, 11.8) −2.0 (−11.7, 8.8) 3.6 (−7.4, 16.0)
MCPP 5.3 (−6.2, 18.3) 3.4 (−9.8, 18.6) 3.7 (−5.7, 14.1) 6.2 (−7.4, 21.8)
MEP 3.0 (−7.9, 15.2) −15.0 (−25.1, −3.6)* −0.6 (−10.2, 10.2) −3.4 (−14.6, 9.4)
ΣDEHP 11.2 (1.5, 21.9)* 8.2 (−3.2, 21.0) 4.6 (−4.8, 14.9) 11.2 (−1.4, 25.3)
ΣDBP 8.5 (−0.7, 18.5) −5.8 (−15.4, 4.8) 7.6 (−2.6, 18.7) 6.5 (−5.5, 20.1)
Testosterone
BPA 9.0 (−16.6, 42.3) 14.8 (−12.3, 50.4) 10.1 (−16.7, 45.5) 33.4 (−6.1, 89.4)
MBzP 17.1 (−5.9, 45.7) −2.5 (−25.1, 27.0) 3.1 (−23.9, 39.7) 14.6 (−17.1, 58.5)
MCPP 9.9 (−18.8, 48.6) 14.8 (−18.8, 62.4) 9.5 (−17.1, 44.6) 27.2 (−14.2, 88.7)
MEP 30.3 (−2.0, 73.2) −2.8 (−30.3, 35.6) −8.2 (−31.8, 23.5) 6.6 (−25.4, 52.5)
ΣDEHP 10.8 (−13.1, 41.4) 2.5 (−23.1, 36.5) 8.4 (−17.6, 42.7) 20.1 (−15.2, 70.1)
ΣDBP 4.8 (−17.0, 32.4) −2.9 (−26.1, 27.7) −9.3 (−32.1, 21.2) −0.3 (−29.6, 41.2)
SHBG
BPA −0.8 (−11.1, 10.6) 4.7 (−6.2, 16.9) 5.3 (−5.0, 16.8) 5.6 (−7.4, 20.5)
MBzP 5.1 (−3.9, 14.9) −1.2 (−11.3, 10.0) 15.2 (3.2, 28.5)* 10.2 (−2.2, 24.2)
MCPP 4.6 (−7.4, 18.3) −2.3 (−15.2, 12.5) 14.4 (3.5, 26.5)* 12.5 (−2.8, 30.2)
MEP 3.4 (−8.1, 16.3) −2.8 (−15.0, 11.3) 4.6 (−6.4, 16.8) 4.2 (−8.8, 19.0)
ΣDEHP −0.2 (−9.7, 10.2) 1.9 (−9.3, 14.4) 8.4 (−2.1, 19.9) 8.2 (−4.9, 23.1)
ΣDBP 1.1 (−8.0, 11.2) −6.5 (−16.2, 4.4) 12.3 (1.1, 24.9)* 5.2 (−7.6, 19.7)
DHEA-S
BPA 3.5 (−10.8, 20.0) −12.1 (−23.9, 1.6) 1.2 (−12.4, 16.9) −1.9 (−18.4, 18.0)
MBzP −0.9 (−12.3, 12.1) −15.9 (−26.8, −3.4)* −4.4 (−18.3, 11.8) −11.9 (−25.5, 4.0)
MCPP −2.3 (−17.4, 15.5) −7.4 (−23.3, 11.8) −5.0 (−17.6, 9.7) −6.0 (−23.5, 15.4)
MEP −4.9 (−19.0, 11.7) −9.2 (−24.1, 8.6) −7.7 (−20.8, 7.5) −9.4 (−24.7, 8.9)
ΣDEHP 0.9 (−11.9, 15.5) −4.4 (−18.2, 11.7) −0.1 (−13.3, 15.1) 0.5 (−16.2, 20.5)
ΣDBP −1.1 (−13.1, 12.6) −7.3 (−20.0, 7.5) −13.5 (−25.3, 0.2) −10.8 (−25.4, 6.7)
Inhibin B
BPA 3.0 (−7.7, 14.8) 11.8 (0.4, 24.6)* −1.8 (−12.0, 9.6) 8.8 (−5.2, 24.9)
MBzP 2.7 (−6.1, 12.4) −2.9 (−12.8, 8.1) −6.5 (−17.0, 5.3) −5.6 (−16.8, 7.2)
MCPP 4.2 (−7.8, 17.8) 8.4 (−5.9, 24.7) −0.9 (−11.2, 10.6) 4.9 (−10.2, 22.5)
MEP −1.6 (−12.6, 10.7) −1.3 (−13.9, 13.0) −13.6 (−22.9, −3.2)* −8.8 (−20.6, 4.9)
ΣDEHP 8.1 (−2.0, 19.3) 7.0 (−4.7, 20.2) −2.9 (−12.8, 8.2) 5.1 (−8.3, 20.5)
ΣDBP 2.9 (−6.4, 13.2) 8.3 (−3.0, 21.0) −4.1 (−14.4, 7.5) 2.3 (−10.7, 17.2)
*p < 0.05
aAdjusted for child age, BMI z-score, and urinary specific gravity
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measures in Table 3. With the exception of MEP at visit
1, maternal phthalate metabolite and BPA levels at pre-
natal visits 1 and 3, as well as the GM of concentrations
across pregnancy, were all associated with reduced odds
of adrenarche (PH >1) after adjustment for child age and
BMI z-score (Table 3). However, MBzP and ΣDEHP at
visit 3, and the GM of MBzP across pregnancy were the
only associations to reach statistical significance. Puber-
tal onset (GD >1 or TV >3 mL) was not associated with
prenatal phthalate metabolite and BPA concentrations
measured at any study visit or with GM concentrations
across pregnancy. The one exception to this was reduced
odds of TV > 3 mL associated with higher GM MBzP
concentrations.
Population means (fixed effects) and distributions of
individual exposure intercepts and slopes (random effects)
from mixed models evaluating the effects of gestational
age on prenatal phthalate and BPA levels are presented in
Additional file 1: Table S4. When we considered individ-
ual’s exposure intercept and slope as predictors of peripu-
bertal hormone levels we observed relationships that were
consistent with what we observed using the visit specific
concentrations. For instance, an IQR increase in the
ΣDEHP intercept, which represents exposure in the first
trimester, was associated with 15% higher peripubertal es-
tradiol concentrations (Table 4). This is consistent with
our main analyses, in which we observed 11% higher es-
tradiol with an IQR increase ΣDEHP at visit 1 (Table 2).
Further, an IQR increase in MEP slope, which represents
the change in exposure across pregnancy, was associated
with 13% higher inhibin B (Table 4), while in our main
analysis an IQR increase in MEP levels at prenatal visit 3
was significantly associated with 14% higher inhibin B
(Table 2). Consistent with results from our main analysis in
Table 3, estimated exposure at 7 weeks (exposure inter-
cepts) were not significantly associated with odds of pu-
berty or adrenarche (GD >1, TV >3, or PH >1) (Table 5),
although estimated relationships were in similar directions.
Discussion
We investigated maternal urinary phthalate metabolite
and BPA concentrations during the first, second, and
third trimesters of pregnancy in relation to peripubertal
reproductive hormone levels and measures of sexual
maturation in male offspring in order to identify poten-
tial windows of exposure susceptibility during in utero
Table 3 Odds of Tanner stage >1 or TV >3 ml associated with an IQR increase in trimester-specific, SG-corrected in utero urinary
phthalate metabolite or BPA concentrationa
Visit 1 (n = 90) Visit 2 (n = 89) Visit 3 (n = 105) Prenatal GM (n = 106)
OR/IQR (95% CI) OR/IQR (95% CI) OR/IQR (95% CI) OR/IQR (95% CI)
Genital Development
BPA 0.71 (0.39, 1.28) 1.41 (0.78, 2.54) 0.93 (0.53, 1.61) 1.04 (0.5, 2.14)
MBzP 0.95 (0.58, 1.55) 0.98 (0.57, 1.68) 0.71 (0.37, 1.36) 0.75 (0.37, 1.51)
MCPP 1.2 (0.61, 2.36) 1.16 (0.53, 2.54) 0.97 (0.53, 1.77) 1.14 (0.48, 2.73)
MEP 1.5 (0.79, 2.85) 1.17 (0.56, 2.48) 1.09 (0.58, 2.03) 1.27 (0.58, 2.81)
ΣDEHP 0.99 (0.56, 1.74) 0.85 (0.46, 1.57) 0.71 (0.4, 1.29) 0.77 (0.37, 1.62)
ΣDBP 0.77 (0.47, 1.27) 0.86 (0.48, 1.52) 0.59 (0.31, 1.13) 0.57 (0.27, 1.21)
Pubic Hair
BPA 0.2 (0.02, 2.76) 1.1 (0.31, 3.9) 0.42 (0.13, 1.36) 0.72 (0.19, 2.73)
MBzP 0.13 (0.01, 1.56) 0.99 (0.26, 3.73) 0.18 (0.03, 0.97)* 0.31 (0.1, 0.93)*
MCPP 0.33 (0.02, 4.72) 5.99 (0.5, 72.02) 0.47 (0.16, 1.37) 0.5 (0.11, 2.26)
MEP 2.04 (0.36, 11.58) 1.31 (0.22, 7.85) 0.44 (0.15, 1.24) 0.52 (0.17, 1.6)
ΣDEHP 0 (0, 542.1) 2.22 (0.28, 17.34) 0.27 (0.07, 0.99)* 0.16 (0.03, 1.02)
ΣDBP 0.28 (0.02, 3.85) 2.68 (0.48, 15.08) 0.36 (0.13, 1.06) 0.39 (0.11, 1.42)
Testicular Volume
BPA 1.28 (0.67, 2.45) 2.01 (0.94, 4.28) 1.34 (0.68, 2.66) 2.29 (0.87, 5.98)
MBzP 0.7 (0.39, 1.23) 0.62 (0.3, 1.29) 0.73 (0.33, 1.6) 0.4 (0.16, 1)*
MCPP 0.56 (0.25, 1.27) 1.59 (0.6, 4.23) 1.03 (0.5, 2.12) 1.07 (0.36, 3.19)
MEP 1.33 (0.64, 2.76) 0.75 (0.31, 1.86) 1.32 (0.6, 2.91) 1.16 (0.44, 3.06)
ΣDEHP 1.21 (0.64, 2.3) 0.99 (0.49, 2) 1.5 (0.75, 3) 1.94 (0.7, 5.34)
ΣDBP 1 (0.54, 1.84) 1.66 (0.85, 3.25) 0.88 (0.44, 1.75) 1.35 (0.54, 3.4)
*p < 0.05
aAdjusted for child age and BMI z-score
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development. Our findings suggest that compared to
phthalate exposure early in pregnancy, exposure specific-
ally during the third trimester is associated with reduced
odds of adrenarche and a corresponding increase in
serum SHBG concentrations. In addition, we observed
an increase in peripubertal serum estradiol associated
with DEHP exposure specifically in the first trimester of
in utero development.
In comparison with our previous evaluation of third
trimester phthalate levels and sexual maturation in males
in this same population [17], estimated associations for
first and second trimester exposure also indicated reduced
odds of adrenarche (PH >1) with phthalate exposure, al-
though associations did not reach statistical significance.
Consistent with reduced odds of adrenarche, we observed
reduced peripubertal serum DHEA-S concentrations in
relation to several phthalate metabolite levels across
pregnancy, although only MBzP in the second trimester
was statistically significant (Table 2).
Two prior studies examined associations between
markers of in utero phthalate exposure and reproductive
hormone concentrations in cord blood, one of which re-
ported no relationship between third trimester maternal
urinary phthalate levels and hormones among male new-
borns [27]. However, the second study reported associa-
tions between third trimester MEHP levels in maternal
blood and reduced testosterone to estradiol ratios and in-
hibin B among males [10]. In addition, a cross-sectional
study of perinatal phthalate exposure reported that MEP
and MBP concentrations in breast milk were associated
with increased luteinizing hormone to free testosterone
ratios and SHBG in male infants at three months of age
[28]. Findings from the latter two studies, as well as the
associations between several phthalate metabolite levels
during the third trimester and higher peripubertal
SHBG concentrations reported in the present study, are
consistent with anti-androgen exposure.
A number of studies have examined associations be-
tween in utero phthalate exposure and fetal reproductive
tract development in males. One of the first studies of
phthalate exposure found that maternal urinary MEP,
MBP, MBzP, and MiBP levels during the third trimester
were associated with shortened AGD in male infants
[12]. In a recent study, researchers found that maternal
urinary DEHP metabolite concentrations in the first tri-
mester, but not the second and third trimesters, were in-
versely associated with this same outcome measure [13].
This is consistent with what is currently known about
male reproductive development, as AGD is determined by
androgen action during the masculinizing programming
Table 4 Relationships between IQR increases in estimated intercepts and slopes of exposure across in utero development and
hormone levels at 8–14 years (n = 104)a
Estradiol Testosterone SHBG DHEA-S Inhibin B
%Δ/IQR (95% CI) %Δ/IQR (95% CI) %Δ/IQR (95% CI) %Δ/IQR (95% CI) %Δ/IQR (95% CI)
BPAb Intercept −3.6 (−13.6, 7.5) 12.8 (−16, 51.6) 2.3 (−8.8, 14.9) −0.9 (−15.1, 15.7) 5.7 (−6.1, 18.9)
Slope n/a n/a n/a n/a n/a
MBzPb Intercept 6.1 (−4.5, 17.9) 20.4 (−9.5, 60.1) 9.8 (−1.7, 22.6) −5.4 (−18.5, 9.9) 1.5 (−9.6, 13.8)
Slope n/a n/a n/a n/a n/a
MCPP Intercept 8.3 (−5.3, 24.0) 9.4 (−24.2, 57.8) 15.3 (0.3, 32.6)* −7.1 (−23.2, 12.5) 5.6 (−8.7, 22.3)
Slope 2.7 (−9.7, 16.9) −0.5 (−30.0, 41.3) 14.5 (0.2, 30.9)* −7.3 (−22.8, 11.4) −1.4 (−14.3, 13.3)
MEP Intercept −6.3 (−17.2, 6.1) 6.7 (−23.5, 48.8) 4.9 (−8.1, 19.7) −6.7 (−21.8, 11.3) −6.8 (−18.3, 6.4)
Slope −7.4 (−16.8, 3.1) −22.1 (−41.6, 3.8) 0.0 (−10.8, 12.1) −4.8 (−18.3, 10.9) −12.9 (−22.3, −2.4)*
ΣDEHP Intercept 15.0 (3.2, 28.2)* 6.2 (−21.6, 43.9) 9.4 (−2.8, 23.0) 0.4 (−14.4, 17.7) 6.6 (−5.4, 20.2)
Slope 0.9 (−9.7, 12.8) −9.1 (−33.3, 24.0) 9.2 (−3.2, 23.0) −2.2 (−16.8, 15.1) −6.6 (−17.3, 5.6)
ΣDBP Intercept 8.7 (−7.0, 27.1) −12.4 (−42.6, 33.7) 11.2 (−5.7, 31.1) −14.9 (−31.7, 5.9) 5.1 (−11.3, 24.5)
Slope 0.7 (−12.1, 15.2) −19.8 (−44.4, 15.7) 10.5 (−4.2, 27.4) −14.4 (−29.2, 3.6) −2.7 (−15.9, 12.7)
*p < 0.05
aAdjusted for child age and BMI z-score. bIntercept and slope highly correlated (BPA r = −0.82, MBzP r = −0.99), only intercept included in model
Table 5 Relationships between an IQR increase in estimated
exposure at 7 weeks gestation (intercepts) and odds of Tanner
stage >1 or TV >3 mL (n = 102)a
Genital Development Pubic Hair Testicular Volume
OR/IQR (95% CI) OR/IQR (95% CI) OR/IQR (95% CI)
Intercept
BPA 0.86 (0.46, 1.58) 0.76 (0.20, 2.98) 1.67 (0.79, 3.56)
MBzP 0.82 (0.44, 1.52) 0.54 (0.18, 1.62) 0.55 (0.25, 1.22)
MCPP 1.17 (0.64, 2.15) 1.33 (0.43, 4.15) 0.66 (0.31, 1.43)
MEP 1.33 (0.67, 2.61) 1.08 (0.33, 3.54) 1.26 (0.56, 2.86)
ΣDEHP 0.82 (0.46, 1.45) 0.41 (<0.001, 1.46) 1.29 (0.65, 2.56)
ΣDBP 0.65 (0.34, 1.23) 0.94 (0.29, 3.09) 1.29 (0.56, 2.96)
aAdjusted for child age and BMI z-score
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window, which in humans is thought to be between weeks
7–15 of in utero development [19]. Interestingly, we ob-
served a similar relationship between DEHP metabolites
in the first trimester and increased serum estradiol levels
in males at 8–14 years of age, but saw no association with
exposure during later trimesters. However, we did not ob-
serve associations between in utero phthalate exposure
and peripubertal testosterone levels, as we might expect
given phthalates anti-androgenic activity.
One previous study reported positive correlations be-
tween cord blood levels of BPA with inhibin B and testos-
terone among male infants [11], which although measured
in different media and at different time points, is consist-
ent with our finding of increased peripubertal inhibin B
concentrations in relation to urinary BPA at prenatal visit
2. However, in the current study, prenatal BPA levels were
not associated with any other hormone or measure of sex-
ual maturation among boys at 8–14 years of age.
Although mechanisms by which in utero phthalate ex-
posure may alter fetal and pubertal reproductive develop-
ment are unclear, animal studies have shown that prenatal
phthalate exposure may interfere with differentiation and
function of both Sertoli and Leydig cells, as well as testos-
terone production in the testes [29–35], possibly by dis-
rupting the hypothalamus-pituitary-gonadal axis and/or
via induction of oxidative stress [36–38]. Steroid hormone
levels are important in all phases of fetal male reproduct-
ive system development, which begins at gestational week
6 with the differentiation of gonadal tissue into fetal testes
and is mostly complete by week 15, although growth and
testicular descent continue through the third trimester.
Considering the complexity of this process throughout the
gestational period, there is substantial potential for differ-
ential windows of susceptibility to exposure during this
time. Indeed, both animal and human studies have dem-
onstrated that exposure to androgens, anti-androgens, or
estrogens during different periods of in utero development
have different effects on the newborn male reproductive
tract [13, 18, 19, 39, 40]. To our knowledge, the current
study is the first to investigate the long term impact of
phthalate and BPA exposure during specific periods of in
utero development on male reproductive development
during puberty.
Our analyses examining exposure levels and rates of
change across pregnancy in relation to reproductive hor-
mones and sexual maturation enabled us to look at ex-
posure across time within the same mother/child pair
rather than at discrete time points. Our findings using
this method were consistent with those from our main
analysis, thus our conclusions are robust to the method
of analysis used.
Our analysis was limited by a relatively small sample
size, and we made a large number of comparisons, in-
creasing the likelihood of chance findings. Also, few boys
had a PH Tanner stage >1, which may have resulted in
unstable effect estimates (i.e. large confidence intervals).
However, we are currently conducting an additional
follow-up of over 550 children in the ELEMENT cohort,
including boys in the current analysis who are now 9–
17 years of age, for repeated hormone measurements
and assessments of sexual maturation. Timing of the
prenatal period may also have influenced our findings,
as decreases in exposure to some phthalates have been
demonstrated in the US since the early 2000s [41]. Be-
cause our study included a range of ages (8–14 years),
older boys may have been more likely to have higher in
utero phthalate exposure as well as to have begun pu-
berty. However, it is not known if these same exposure
trends occurred in Mexico during the time of mother’s
enrollment in this study (1997–2004), and when we add-
itionally adjusted our models for year of conception, our
results did not materially change. We also measured
serum hormones using standardized immunoassays ra-
ther than the preferred method of LC/MS-MS, although
hormone concentrations were all above their respective
LODs, with the exception of testosterone in 12 samples.
In addition, hormone concentrations were measured at
only one time point and not adjusted for time of day,
leading to potential non-differential misclassification due
to diurnal variation. Another limitation was measurements
of urinary phthalate metabolites at only one time point
during each trimester, which may not fully characterize ex-
posure across in utero development.
Conclusions
Our results suggest that associations between in utero
phthalate and BPA exposure and peripubertal measures
of male reproductive development are dependent on the
timing of that exposure during gestation. These findings
are consistent with current understanding of male repro-
ductive tract development during the fetal and pubertal
periods, and with reports from animal research. Although
our findings need to be repeated in larger and more ma-
ture populations, future epidemiological studies of in utero
exposure to endocrine disrupting chemicals and repro-
ductive development should consider potential windows
of susceptibility.
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volume ≤ 3 ml vs > 3 ml. Table S3. Odds of Tanner stage >1 or TV >3 ml
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Watkins et al. Environmental Health  (2017) 16:69 Page 8 of 10
Abbreviations
AGD: Anogenital distance; BMI: Body mass index; BPA: Bisphenol A;
CI: Confidence interval; DBP: Dibutyl phthalate; DEHP: Di-2-ethylhexyl
phthalate; DHEA-S: Dehydroepiandrosterone sulfate; EDC: Endocrine
disrupting chemical; ELEMENT: Early Life Exposure in Mexico to
Environmental Toxicants; GD: Tanner genital stage; GM: Geometric mean;
ICC: Intraclass correlation coefficient; ID-LC-MS/MS: Isotope dilution–liquid
chromatography–tandem mass spectrometry; IQR: Interquartile range;
LOD: Limit of detection; MBzP: Monobenzyl phthalate; MCPP: Mono-3-
carboxypropyl phthalate; MECPP: Mono-2-ethyl-5-carboxypentyl phthalate;
MEHHP: Mono-2-ethyl-5-hydroxyhexyl phthalate; MEHP: Mono-2-ethylhexyl
phthalate; MEOHP: Mono-2-ethyl-5-oxohexyl phthalate; MEP: Monoethyl
phthalate; MiBP: Monoisobutyl phthalate; MnBP: Mono-n-butyl phthalate;
OR: Odds ratio; PH: Tanner pubic hair stage; SG: Specific gravity; SHBG: Sex
hormone-binding globulin; TV: Testicular volume
Acknowledgements
We would like to thank ABC Hospital for providing facilities for this research.
Funding
This work was supported by grants P01ES022844 from the National Institute
for Environmental Health Sciences (NIEHS), and RD 83543601 from the US
Environmental Protection Agency (US EPA). Its contents are solely the
responsibility of the grantee and do not necessarily represent the official
views of the US EPA. Further, the US EPA does not endorse the purchase of
any commercial products or services mentioned in the publication. This work
was also supported and partially funded by the National Institute of Public
Health, Ministry of Health of Mexico.
Availability of data and materials
Please contact author for data requests.
Authors’ contributions
DJW, analyzed and interpreted data, drafted and revised manuscript; BNS,
conception of study and study design, guided data analysis and interpretation,
revised manuscript; MMT-R., conception of study and study design, interpreted
data, revised manuscript; JML, interpreted data, revised manuscript; AM-G, col-
lection of data, revised manuscript; CB-G, collection of data, revised manuscript;
KEP, conception of study and study design, interpreted data, revised manuscript;
JDM, conception of study and study design, interpreted data, revised manu-
script. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Research protocols were approved by the ethics and research committees of
the Mexico National Institute of Public Health and the University of Michigan
(HUM00034344), and all participants provided informed consent prior to
enrollment.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Environmental Health Sciences, University of Michigan
School of Public Health, 6611C SPH I, 1415 Washington Heights, Ann Arbor,
MI 48109, USA. 2Department of Biostatistics, University of Michigan School of
Public Health, Ann Arbor, MI, USA. 3Center for Nutrition and Health Research,
Instituto Nacional de Salud Pública, MOR, Cuernavaca, MEXICO. 4Pediatric
Endocrinology, Child Health Evaluation and Research Unit (CHEAR), University
of Michigan, Ann Arbor, MI, USA. 5American British Cowdray (ABC) Hospital,
Mexico City, MEXICO. 6Department of Nutritional Sciences, University of
Michigan School of Public Health, Ann Arbor, MI, USA. 7Center for Human
Growth and Development, University of Michigan, Ann Arbor, MI, USA.
Received: 23 November 2016 Accepted: 11 June 2017
References
1. Zoeller RT, Brown TR, Doan LL, Gore AC, Skakkebaek NE, Soto AM, et al.
Endocrine-disrupting chemicals and public health protection: A statement of
principles from The Endocrine Society. Endocrinology. 2012;153(9):4097–110.
2. Silva MJ, Barr DB, Reidy JA, Malek NA, Hodge CC, Caudill SP, et al. Urinary
levels of seven phthalate metabolites in the US population from the
National Health and Nutrition Examination Survey (NHANES) 1999–2000.
Environ Health Perspect. 2004;112(3):331–8.
3. Teitelbaum SL, Britton JA, Calafat AM, Ye X, Silva MJ, Reidy JA, et al.
Temporal variability in urinary concentrations of phthalate metabolites,
phytoestrogens and phenols among minority children in the United States.
Environ Res. 2008;106(2):257–69.
4. Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. Exposure of the U.S.
population to bisphenol A and 4-tertiary-octylphenol: 2003–2004. Environ
Health Perspect. 2008;116(1):39–44.
5. Mok-Lin E, Ehrlich S, Williams PL, Petrozza J, Wright DL, Calafat AM, et al.
Urinary bisphenol A concentrations and ovarian response among women
undergoing IVF. Int J Androl. 2010;33(2):385–93.
6. Ehrlich S, Williams PL, Missmer SA, Flaws JA, Ye XY, Calafat AM, et al. Urinary
bisphenol A concentrations and early reproductive health outcomes among
women undergoing IVF. Hum Reprod. 2012;27(12):3583–92.
7. Meeker JD, Calafat AM, Hauser R. Urinary metabolites of di(2-ethylhexyl)
phthalate are associated with decreased steroid hormone levels in adult
men. J Androl. 2009;30(3):287–97.
8. Pan G, Hanaoka T, Yoshimura M, Zhang S, Wang P, Tsukino H, et al.
Decreased serum free testosterone in workers exposed to high levels of
di-n-butyl phthalate (DBP) and di-2-ethylhexyl phthalate (DEHP): a cross-
sectional study in China. Environ Health Perspect. 2006;114(11):1643–8.
9. Sathyanarayana S, Barrett E, Butts S, Wang C, Swan SH. Phthalate exposure
and reproductive hormone concentrations in pregnancy. Reproduction.
2014;147(4):401–9.
10. Araki A, Mitsui T, Miyashita C, Nakajima T, Naito H, Ito S, et al. Association
between maternal exposure to di(2-ethylhexyl) phthalate and reproductive
hormone levels in fetal blood: the Hokkaido study on environment and
children's health. PLoS One. 2014;9(10):e109039.
11. Fenichel P, Dechaux H, Harthe C, Gal J, Ferrari P, Pacini P, et al.
Unconjugated bisphenol A cord blood levels in boys with descended or
undescended testes. Hum Reprod. 2012;27(4):983–90.
12. Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Calafat AM, et al. Decrease in
anogenital distance among male infants with prenatal phthalate exposure.
Environ Health Perspect. 2005;113(8):1056–61.
13. Martino-Andrade AJ, Liu F, Sathyanarayana S, Barrett ES, Redmon JB,
Nguyen RH, et al. Timing of prenatal phthalate exposure in relation to
genital endpoints in male newborns. Andrology. 2016;4:585–93.
14. Swan SH, Sathyanarayana S, Barrett ES, Janssen S, Liu F, Nguyen RH, et al.
First trimester phthalate exposure and anogenital distance in newborns.
Hum Reprod. 2015;30(4):963–72.
15. Eisenberg ML, Hsieh MH, Walters RC, Krasnow R, Lipshultz LI. The
relationship between anogenital distance, fatherhood, and fertility in adult
men. PLoS One. 2011;6(5):e18973.
16. Skakkebaek NE, Rajpert-De Meyts E, Buck Louis GM, Toppari J, Andersson
AM, Eisenberg ML, et al. Male reproductive disorders and fertility trends:
Influences of environment and genetic susceptibility. Physiol Rev. 2016;
96(1):55–97.
17. Ferguson KK, Peterson KE, Lee JM, Mercado-Garcia A, Goldenberg CB,
Tellez-Rojo MM, et al. Prenatal and peripubertal phthalates and
bisphenol A in relation to sex hormones and puberty in boys. Reprod
Toxicol. 2014;47:70–6.
18. Macleod DJ, Sharpe RM, Welsh M, Fisken M, Scott HM, Hutchison GR, et al.
Androgen action in the masculinization programming window and
development of male reproductive organs. Int J Androl. 2010;33(2):279–87.
19. Welsh M, Saunders PT, Fisken M, Scott HM, Hutchison GR, Smith LB, et al.
Identification in rats of a programming window for reproductive tract
masculinization, disruption of which leads to hypospadias and
cryptorchidism. J Clin Invest. 2008;118(4):1479–90.
20. Lewis RC, Meeker JD, Peterson KE, Lee JM, Pace GG, Cantoral A, et al.
Predictors of urinary bisphenol A and phthalate metabolite concentrations
in Mexican children. Chemosphere. 2013;93(10):2390–8.
Watkins et al. Environmental Health  (2017) 16:69 Page 9 of 10
21. World Health Organization. Growth reference data for 5–19 years. 2007.
http://www.who.int/growthref/en/. Accessed 15 Aug 2016.
22. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls.
Arch Dis Child. 1969;44(235):291–303.
23. Mouritsen A, Aksglaede L, Soerensen K, Hagen CP, Petersen JH, Main KM, et
al. The pubertal transition in 179 healthy Danish children: associations
between pubarche, adrenarche, gonadarche, and body composition. Eur J
Endocrinol. 2013;168(2):129–36.
24. Spiegelman D. The SAS ICC9 Macro. 2016. https://www.hsph.harvard.edu/
donna-spiegelman/software/icc9/. Accessed 15 August 2016.
25. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study
of the number of events per variable in logistic regression analysis. J Clin
Epidemiol. 1996;49(12):1373–9.
26. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in
logistic and Cox regression. Am J Epidemiol. 2007;165(6):710–8.
27. Lin LC, Wang SL, Chang YC, Huang PC, Cheng JT, Su PH, et al. Associations
between maternal phthalate exposure and cord sex hormones in human
infants. Chemosphere. 2011;83(8):1192–9.
28. Main KM, Mortensen GK, Kaleva MM, Boisen KA, Damgaard IN, Chellakooty
M, et al. Human breast milk contamination with phthalates and alterations
of endogenous reproductive hormones in infants three months of age.
Environ Health Perspect. 2006;114(2):270–6.
29. Fisher JS, Macpherson S, Marchetti N, Sharpe RM. Human ‘testicular
dysgenesis syndrome’: a possible model using in-utero exposure of the rat
to dibutyl phthalate. Hum Reprod. 2003;18(7):1383–94.
30. Wang Y, Yang Q, Liu W, Yu M, Zhang Z, Cui X. Di(2-ethylhexyl) phthalate
exposure in utero damages sertoli cell differentiation via disturbance of sex
determination pathway in fetal and postnatal mice. Toxicol Sci. 2016;152:53–61.
31. Aydogan Ahbab M, Barlas N. Influence of in utero di-n-hexyl phthalate and
dicyclohexyl phthalate on fetal testicular development in rats. Toxicol Lett.
2015;233(2):125–37.
32. Culty M, Thuillier R, Li W, Wang Y, Martinez-Arguelles DB, Benjamin CG, et al.
In utero exposure to di-(2-ethylhexyl) phthalate exerts both short-term and
long-lasting suppressive effects on testosterone production in the rat. Biol
Reprod. 2008;78(6):1018–28.
33. Foster PM. Disruption of reproductive development in male rat offspring
following in utero exposure to phthalate esters. Int J Androl. 2006;29(1):140–7.
34. Kumar N, Srivastava S, Roy P. Impact of low molecular weight phthalates in
inducing reproductive malfunctions in male mice: Special emphasis on
Sertoli cell functions. Gen Comp Endocrinol. 2015;215:36–50.
35. Shultz VD, Phillips S, Sar M, Foster PM, Gaido KW. Altered gene profiles in
fetal rat testes after in utero exposure to di(n-butyl) phthalate. Toxicol Sci.
2001;64(2):233–42.
36. Ha M, Guan X, Wei L, Li P, Yang M, Liu C. Di-(2-ethylhexyl) phthalate inhibits
testosterone level through disturbed hypothalamic-pituitary-testis axis and
ERK-mediated 5alpha-Reductase 2. Sci Total Environ. 2016;563–564:566–75.
37. Sedha S, Kumar S, Shukla S. Role of oxidative stress in male reproductive
dysfunctions with reference to phthalate compounds. Urol J. 2015;12(5):2304–16.
38. Sobarzo CM, Rosana Nde M, Livia L, Berta D, Schteingart HF. Mono-(2-
ethylhexyl) phthalate (MEHP) affects intercellular junctions of Sertoli cell: A
potential role of oxidative stress. Reprod Toxicol. 2015;58:203–12.
39. Zheng Z, Armfield BA, Cohn MJ. Timing of androgen receptor disruption
and estrogen exposure underlies a spectrum of congenital penile
anomalies. Proc Natl Acad Sci U S A. 2015;112(52):E7194–203.
40. Nef S, Parada LF. Hormones in male sexual development. Genes Dev.
2000;14(24):3075–86.
41. Zota AR, Calafat AM, Woodruff TJ. Temporal trends in phthalate exposures:
Findings from the national health and nutrition examination survey, 2001–2010.
Environ Health Perspect. 2014;122:235–41.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Watkins et al. Environmental Health  (2017) 16:69 Page 10 of 10
